Clinical trial
Open-Label Efficacy and Safety Study of Pozelimab in Patients With…
NCT04209634 · Regeneron Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT04209634 |
|---|---|
| Title | Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) |
| Official title | An Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) |
| Lead sponsor | Regeneron Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | CD55-deficient Protein-losing Enteropathy, CHAPLE |
| Intervention type | Drug |
| Interventions | Pozelimab |
| Enrollment | 10 |
| Start date | Jan 27, 2020 |
| Primary completion | Nov 9, 2021 |
| Completion | May 2, 2024 |
| First posted | Dec 24, 2019 |
| Last update posted | Aug 29, 2025 |
| Countries | Thailand, Turkey (Türkiye), United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: